Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $30,034.80 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of the business’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the transaction, the general counsel now owns 486,027 shares in the company, valued at approximately $7,086,273.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46.

Liquidia Stock Performance

Shares of LQDA opened at $13.29 on Friday. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99. The firm’s 50-day simple moving average is $14.74 and its two-hundred day simple moving average is $10.97.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The firm had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. As a group, equities analysts expect that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LQDA has been the topic of several research analyst reports. HC Wainwright boosted their price target on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Liquidia by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 2,843,922 shares of the company’s stock worth $34,212,000 after buying an additional 69,524 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Liquidia in the fourth quarter worth approximately $849,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Liquidia by 9.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock worth $137,000 after buying an additional 989 shares in the last quarter. Bluefin Capital Management LLC bought a new position in Liquidia during the fourth quarter valued at approximately $302,000. Finally, Barclays PLC lifted its position in Liquidia by 1,105.2% during the fourth quarter. Barclays PLC now owns 103,021 shares of the company’s stock valued at $1,239,000 after purchasing an additional 94,473 shares during the period. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).